SuperworthChampions Oncology free cash flow CSBR
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 31, 2026
- −$6.1M
- Latest quarter, Q1 FY27
- −$547K
- −199% on a year earlier
- Fiscal year 2026
- −$5M
- −172% on the year before
Champions Oncology's free cash flow was −$6.1M over the twelve months to Jul 31, 2026, down 185% on a year earlier.
In its latest quarter, Q1 FY27, it was −$547K, down 199% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2026 | −$5M | −172% |
| FY2025 | $7M | n/a |
| FY2024 | −$7M | −734% |
| FY2023 | $1.1M | −73% |
| FY2022 | $4.1M | n/a |
| FY2021 | −$5M | −824% |
| FY2020 | $685K | −33% |
| FY2019 | $1M | n/a |
| FY2018 | −$2.5M | n/a |
| FY2017 | −$3.6M | n/a |
| FY2016 | −$6.7M | n/a |
| FY2015 | −$9.7M | n/a |
| FY2014 | −$3.7M | n/a |
| FY2013 | −$4.4M | n/a |
| FY2012 | −$5.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | −$547K | −199% | −$6.1M | |
| Q4 FY26 | −$2.2M | −134% | −$5M | |
| Q3 FY26 | −$1.4M | −407% | $3.8M | |
| Q2 FY26 | −$2M | n/a | $5.6M | |
| Q1 FY26 | $554K | +78% | $7.2M | |
| Q4 FY25 | $6.6M | n/a | $7M | |
| Q3 FY25 | $448K | n/a | −$1.4M | |
| Q2 FY25 | −$377K | −174% | −$2.9M | |
| Q1 FY25 | $311K | n/a | −$2M | |
| Q4 FY24 | −$1.8M | n/a | −$7M | |
| Q3 FY24 | −$1M | −223% | −$6.6M | |
| Q2 FY24 | $510K | −81% | −$4.8M |
Against its peers
Companies in Healthcare nearest Champions Oncology's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| CSBRChampions Oncology | −9.3% |
| SPROSpero Therapeutics | n/m |
| LFVNLifevantage | 9.1% |
| APTAlpha Pro Tech | 10.3% |
| ATNMActinium Pharmaceuticals | n/m |
| ICCCImmucell | 4.5% |
| KEQUKewaunee Scientific | 11.5% |
| NEPHNephros | n/m |
| PDEXPro DEX | 3.4% |
| PLXProtalix BioTherapeutics | 3.7% |
| NATRNatures Sunshine Products | 8.5% |
| Peer median | 8.5% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Champions Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.